Literature DB >> 16462886

Cytokine-stimulated phosphorylation of GSK-3 is primarily dependent upon PKCs, not PKB.

Dino Vilimek1, Vincent Duronio.   

Abstract

The regulation of glycogen synthase kinase-3 (GSK-3) by phosphorylation at inhibitory sites has been well documented. In many, but not all, cases, the phosphatidylinositol 3-kinase pathway, and particularly the downstream kinase protein kinase B (PKB)/akt, have been shown to be responsible for GSK-3 phosphorylation. Given that no studies have ever reported cytokine-mediated phosphorylation of GSK-3, we investigated the phosphorylation of this kinase in several hemopoietic cell types in response to either interleukin (IL)-3, IL-4 or granulocyte-macrophage colony stimulating factor (GM-CSF). Each of the cytokines was able to stimulate phosphorylation of the isoforms GSK-3alpha and GSK-3beta. However, only in the case of IL-4 stimulation was there any dependence on PKB for this phosphorylation. We were clearly able to show that PKB was capable of phosphorylating GSK-3 in these cells, but studies using inhibitors of the protein kinase C (PKC) family of kinases have shown that these enzymes are more likely to play a key role in GSK-3 phosphorylation. Cytokine-mediated generation of diacylglycerol was demonstrated, supporting the possible activation of PKC family members. Thus, cytokine-dependent GSK-3 phosphorylation in hemopoietic cells proceeds primarily through PKB independent pathways.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462886     DOI: 10.1139/o05-154

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  17 in total

Review 1.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

2.  Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3.

Authors:  Shuzhen Chen; Wei Cao; Ping Yue; Chunhai Hao; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Res       Date:  2011-08-25       Impact factor: 12.701

3.  Neurotensin phosphorylates GSK-3alpha/beta through the activation of PKC in human colon cancer cells.

Authors:  Qingding Wang; Yuning Zhou; B Mark Evers
Journal:  Neoplasia       Date:  2006-09       Impact factor: 5.715

4.  Phosphoproteomic analysis of AT1 receptor-mediated signaling responses in proximal tubules of angiotensin II-induced hypertensive rats.

Authors:  Xiao C Li; Jia L Zhuo
Journal:  Kidney Int       Date:  2011-06-22       Impact factor: 10.612

5.  Cytokine-induced monocyte MMP-1 is negatively regulated by GSK-3 through a p38 MAPK-mediated decrease in ERK1/2 MAPK activation.

Authors:  Yahong Zhang; Larry M Wahl
Journal:  J Leukoc Biol       Date:  2015-02-24       Impact factor: 4.962

6.  SIL1 Rescued Bip Elevation-Related Tau Hyperphosphorylation in ER Stress.

Authors:  Zan-Chao Liu; Jiang Chu; Li Lin; Jie Song; Lin-Na Ning; Hong-Bin Luo; Shu-Sheng Yang; Yan Shi; Qun Wang; Na Qu; Qi Zhang; Jian-Zhi Wang; Qing Tian
Journal:  Mol Neurobiol       Date:  2015-01-10       Impact factor: 5.590

7.  Targeted knock-in mice expressing mutations of CD28 reveal an essential pathway for costimulation.

Authors:  Lindzy F Dodson; Jonathan S Boomer; Christine M Deppong; Dulari D Shah; Julia Sim; Traci L Bricker; John H Russell; Jonathan M Green
Journal:  Mol Cell Biol       Date:  2009-04-27       Impact factor: 4.272

8.  Inhibition of c-jun N terminal kinase (JNK) improves functional beta cell mass in human islets and leads to AKT and glycogen synthase kinase-3 (GSK-3) phosphorylation.

Authors:  A Fornoni; A Pileggi; R D Molano; N Y Sanabria; T Tejada; J Gonzalez-Quintana; H Ichii; L Inverardi; C Ricordi; R L Pastori
Journal:  Diabetologia       Date:  2007-12-08       Impact factor: 10.122

9.  Loss of TRIM62 expression is an independent adverse prognostic factor in acute myeloid leukemia.

Authors:  Alfonso Quintás-Cardama; Steven M Kornblau; Nianxiang Zhang; Yi Hua Qiu; Sean Post; Chad J Creighton; Jorge Cortes; Kevin R Coombes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-08-12

10.  Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.

Authors:  Dawn Eggert; Prasanta K Dash; Nawal Serradji; Chang-Zhi Dong; Pascal Clayette; Francoise Heymans; Huanyu Dou; Santhi Gorantla; Harris A Gelbard; Larisa Poluektova; Howard E Gendelman
Journal:  J Neuroimmunol       Date:  2009-06-21       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.